It is reported that the new crown vaccine manufacturer Koxing has vaccinated 90% of its employees.

Some of the world’s most advanced new crown vaccines are already being used under emergency plans,media BGR reported. A vaccine manufacturer from China has quietly offered its Phase 3 COVID-19 vaccine drug voluntarily to about 90 percent of its employees and family members. The plan highlights China’s aggressive emergency vaccination program for high-risk groups. At least three vaccines in our country are in phase 3 trials, although each vaccine has been urgently approved.

It is reported that the new crown vaccine manufacturer Koxing has vaccinated 90% of its employees.

Sinovac, which develops the new crown vaccine, says it has quietly offered the drug to 90 per cent of its employees and their families, according to a new report. That equates to about 2,000 to 3,000 Koxing employees and their families, according to a statement to Reuters by the company’s CEO, Yu Weidong. The executive explained that under current domestic regulations, the drug was provided on a voluntary basis. “As a vaccine developer and manufacturer, an outbreak could have a direct impact on our vaccine production,” the CEO said. “

Kosin is the maker of CoronaVac, a vaccine candidate that has been shown to cause an immune response without significant side effects. Clinical trials began in mid-April and should be completed by mid-December. The company has published a study on the first phase of the trial. Data collected from projects including Sinovac employees and their families can be used to prove that vaccines are safe, but these data will not be included in Phase 3 trials because they are not part of the study.

He and his family were vaccinated against the new crown, he said. All Kosing employees or family members who choose to be vaccinated will be informed of the possible side effects of the vaccine. The doctor will also conduct an interview before the injection to assess the overall health of the subject. He said the rate of adverse reactions had been “very low”. Possible reactions include fatigue, fever and pain at the injection site, according to previously published test results.